Related Experiment Video
Updated: Aug 30, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Autosomal Dominant Severe Epidermolysis Bullosa Simplex Treated With Dupilumab
Travis Jackson1, Taylor S Davis2, Christopher Castelow2
1University of Missouri School of Medicine, Columbia, Missouri, USA.
Abstract:
Epidermolysis bullosa simplex (EBS) is an inherited mechanobullous disorder with limited systemic treatment options. Emerging evidence suggests that inflammatory pathways and pruritus may significantly contribute to disease severity, creating the possibility for therapeutic targets. This report describes a premature infant with EBS, severe (EBS-sev) and failure to thrive, who was treated with dupilumab at 5 months and 12 days of age. Treatment resulted in sustained improvement in skin integrity and clinical stability, suggesting that dupilumab may be considered as a potential therapeutic option for future cases of EBS.
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Desmosomes
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Renewal of Skin Epidermal Stem Cells